Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies-Reference-Cited by-同舟云学术

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Published:2018-07 Issue:4 Volume:19 Page:331-339
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Hirsch Fred R.,Kerr Keith M.,Bunn Paul A.,Kim Edward S.,Obasaju Coleman,Pérol Maurice,Bonomi Philip,Bradley Jeffrey D.,Gandara David,Jett James R.,Langer Corey J.,Natale Ronald B.,Novello Silvia,Paz-Ares Luis,Ramalingam Suresh S.,Reck Martin^ORCID,Reynolds Craig H.,Smit Egbert F.,Socinski Mark A.,Spigel David R.,Stinchcombe Thomas E.,Vansteenkiste Johan F.,Wakelee Heather,Thatcher Nick

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference85 articles.

1. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

2. Metastatic non–small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Novello;Ann Oncol,2016

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines). Non–small-cell lung cancer. Version 8.2017. 2017. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed: August 4, 2017.

4. Lung cancer in a health area of Spain: incidence, characteristics and survival;Prim;Eur J Cancer Care (Engl),2010

5. Lung cancer in Northern Portugal: a hospital-based study;Hespanhol;Rev Port Pneumol,2013

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung Cancer;Side Effects of Cancer Therapy;2024

2. Recent advance of next-generation sequencing in patients with lung cancer;Expert Review of Molecular Diagnostics;2023-09-26

3. BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective;Frontiers in Oncology;2022-03-31

4. BENEFITS OF ALECTINIB AS FIRST-LINE TREATMENT OF ALK-MUTATED LUNG SQUAMOUS CELL CARCINOMA: A CASE REPORT;ACTA MEDICA MEDITERR;2022

5. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network;Cancer Treatment and Research Communications;2022